Funding
translational
research
grants that will lead to new sarcoma
therapies
Advocating
for increased
government
funding against sarcoma
Creating
alliances
with the biotechnology and pharmaceutical
industries
to rapidly develop new and better
sarcoma treatments
Increasing
public awareness regarding early
detection of sarcoma
Educating
sarcoma
patients
regarding access to optimal sarcoma
care
Advocating
for early access
by sarcoma patients to promising
agents developed for other cancer
types
SUCCEED Trial
Information that may be
helpful to People Diagnosed with Metastatic
Sarcoma regarding the SUCCEED Clinical Trial
Currently Enrolling Patients
ARIAD Pharmaceuticals has
launched an international Phase 3 clinical trial
of deforolimus, a novel mTOR inhibitor, in
patients with metastatic soft-tissue and bone
sarcomas. Patients who are currently
receiving chemotherapy for the treatment of
their sarcoma may wish to discuss the SUCCEED
trial with their doctors to see if it may be
right for them. For more information about
the trial or to find a trial site nearby, you
can visit
www.succeedtrial.com or call toll-free
1-877-621-2303 or internationally 1-617-621-2302
or email at
ClinicalTrials@ARIAD.com
The Website for The Sarcoma Foundation of America,
its contents and programs, is provided for informational and educational
purposes only and is not intended as medical advice nor is it intended
to create any physician-patient or clinical relationship.
Please remember that this information should not substitute professional
medical advice, diagnosis, or treatment. Always seek the advice
of your physician or other qualified healthcare provider with any
questions you may have regarding a medical condition. Never
disregard professional medical advice or delay in seeking medical
advice because of materials read on this Website. The views
or opinions expressed in the resources provided do not necessarily
reflect those of The Sarcoma Foundation of America or its staff.
By using this Website, you accept these:
Terms of Use.
Please read our
Privacy Statement.